Literature DB >> 27774565

The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.

J Ma1,2, H J McMillan3, G Karagüzel4, C Goodin1, J Wasson1, M A Matzinger5, P DesClouds1, D Cram1, M Page1, V N Konji1, B Lentle6, L M Ward7,8.   

Abstract

Boys with vertebral fractures (VF) identified through routine spine radiographs had milder, less symptomatic, and fewer VF compared to those diagnosed with VF following consultation for back pain. Spontaneous (i.e., medication-unassisted) reshaping of fractured vertebral bodies was absent. Long bone fractures were present even before Duchenne muscular dystrophy (DMD) diagnosis in some boys.
INTRODUCTION: The objective of the study was to determine the time to and characteristics of first fractures in Duchenne muscular dystrophy.
METHODS: This study was a retrospective longitudinal study of 30 boys with DMD <18 years. Boys were classified into four groups according to their first fracture: those with VF identified on routine lateral spine radiographs, those with VF diagnosed following consultation for back pain, those with long bone fractures, and those without fractures.
RESULTS: Compared to boys diagnosed with VF as their initial fracture following consultation for back pain, those with VF surveillance radiographs had shorter durations of glucocorticoid (GC) therapy at the time of VF diagnosis (median 1.6 versus 5.3 years, p < 0.01), higher areal (mean ± standard deviation -1.4 ± 0.7 versus -3.1 ± 0.8, p = 0.01), and volumetric (-0.3 ± 0.5 versus -2.6 ± 0.8, p < 0.01) lumbar spine bone mineral density Z-scores, as well as fewer VF (median 1.4 versus 5.2 per person, p < 0.01) and a lower median spinal deformity index (median 1.5 versus 9.5, p < 0.01). Vertebral body reshaping following VF was not observed. Ten boys sustained a long bone fracture as their first fracture at a mean age of 8.9 ± 4.0 years; four of these boys later sustained a total of 27 incident VF.
CONCLUSIONS: Routine lateral spine radiographs led to detection of VF in their earlier stages, vertebral body reshaping following VF was absent, and VF were frequent after the first long bone fracture. These results support the inclusion of a lateral spine radiograph starting at the time of GC initiation as part of routine bone health monitoring in DMD.

Entities:  

Keywords:  Duchenne muscular dystrophy; First fractures; Glucocorticoids; Osteoporosis

Mesh:

Substances:

Year:  2016        PMID: 27774565     DOI: 10.1007/s00198-016-3774-5

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  39 in total

1.  Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome.

Authors:  J Feber; I Gaboury; A Ni; N Alos; S Arora; L Bell; T Blydt-Hansen; C Clarson; G Filler; J Hay; D Hebert; B Lentle; M Matzinger; J Midgley; D Moher; M Pinsk; F Rauch; C Rodd; N Shenouda; K Siminoski; L M Ward
Journal:  Osteoporos Int       Date:  2011-04-15       Impact factor: 4.507

2.  Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study.

Authors:  Celia Rodd; Bianca Lang; Timothy Ramsay; Nathalie Alos; Adam M Huber; David A Cabral; Rosie Scuccimarri; Paivi M Miettunen; Johannes Roth; Stephanie A Atkinson; Robert Couch; Elizabeth A Cummings; Peter B Dent; Janet Ellsworth; John Hay; Kristin Houghton; Roman Jurencak; Maggie Larché; Claire LeBlanc; Kiem Oen; Claire Saint-Cyr; Robert Stein; David Stephure; Shayne Taback; Brian Lentle; Maryann Matzinger; Nazih Shenouda; David Moher; Frank Rauch; Kerry Siminoski; Leanne M Ward
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-01       Impact factor: 4.794

3.  Bone densitometry of the spine and femur in children by dual-energy x-ray absorptiometry.

Authors:  H Kröger; A Kotaniemi; P Vainio; E Alhava
Journal:  Bone Miner       Date:  1992-04

Review 4.  Osteoporosis in Children with Chronic Disease.

Authors:  Wolfgang Högler; Leanne Ward
Journal:  Endocr Dev       Date:  2015-06-12

5.  Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.

Authors:  Davide Gatti; Franco Antoniazzi; Rosangela Prizzi; Vania Braga; Maurizio Rossini; Luciano Tatò; Ombretta Viapiana; Silvano Adami
Journal:  J Bone Miner Res       Date:  2004-12-20       Impact factor: 6.741

6.  The choice of normative pediatric reference database changes spine bone mineral density Z-scores but not the relationship between bone mineral density and prevalent vertebral fractures.

Authors:  Jinhui Ma; Kerry Siminoski; Nathalie Alos; Jacqueline Halton; Josephine Ho; Brian Lentle; MaryAnn Matzinger; Nazih Shenouda; Stephanie Atkinson; Ronald Barr; David A Cabral; Robert Couch; Elizabeth A Cummings; Conrad V Fernandez; Ronald M Grant; Celia Rodd; Anne Marie Sbrocchi; Maya Scharke; Frank Rauch; Leanne M Ward
Journal:  J Clin Endocrinol Metab       Date:  2014-12-11       Impact factor: 5.958

Review 7.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.

Authors:  Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin
Journal:  Lancet Neurol       Date:  2009-11-27       Impact factor: 44.182

8.  Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy.

Authors:  W M King; R Ruttencutter; H N Nagaraja; V Matkovic; J Landoll; C Hoyle; J R Mendell; J T Kissel
Journal:  Neurology       Date:  2007-05-08       Impact factor: 9.910

9.  Spinal deformity index (SDI) is a good predictor of incident vertebral fractures.

Authors:  S Kerkeni; S Kolta; J Fechtenbaum; C Roux
Journal:  Osteoporos Int       Date:  2009-01-10       Impact factor: 4.507

10.  Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.

Authors:  Frank Rauch; Craig F Munns; Christof Land; Moira Cheung; Francis H Glorieux
Journal:  J Bone Miner Res       Date:  2009-07       Impact factor: 6.741

View more
  20 in total

Review 1.  Growth, pubertal development, and skeletal health in boys with Duchenne Muscular Dystrophy.

Authors:  Leanne M Ward; David R Weber
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2019-02       Impact factor: 3.243

2.  Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.

Authors:  Laurie S Conklin; Jesse M Damsker; Eric P Hoffman; William J Jusko; Panteleimon D Mavroudis; Benjamin D Schwartz; Laurel J Mengle-Gaw; Edward C Smith; Jean K Mah; Michela Guglieri; Yoram Nevo; Nancy Kuntz; Craig M McDonald; Mar Tulinius; Monique M Ryan; Richard Webster; Diana Castro; Richard S Finkel; Andrea L Smith; Lauren P Morgenroth; Adrienne Arrieta; Maya Shimony; Mark Jaros; Phil Shale; John M McCall; Yetrib Hathout; Kanneboyina Nagaraju; John van den Anker; Leanne M Ward; Alexandra Ahmet; Michaelyn R Cornish; Paula R Clemens
Journal:  Pharmacol Res       Date:  2018-09-13       Impact factor: 7.658

Review 3.  Clinical management of Duchenne muscular dystrophy: the state of the art.

Authors:  Sonia Messina; Gian Luca Vita
Journal:  Neurol Sci       Date:  2018-09-14       Impact factor: 3.307

Review 4.  The Utility of DXA Assessment at the Forearm, Proximal Femur, and Lateral Distal Femur, and Vertebral Fracture Assessment in the Pediatric Population: 2019 ISCD Official Position.

Authors:  David R Weber; Alison Boyce; Catherine Gordon; Wolfgang Högler; Heidi H Kecskemethy; Madhusmita Misra; Diana Swolin-Eide; Peter Tebben; Leanne M Ward; Halley Wasserman; Christopher Shuhart; Babette S Zemel
Journal:  J Clin Densitom       Date:  2019-07-10       Impact factor: 2.617

Review 5.  Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management.

Authors:  David J Birnkrant; Katharine Bushby; Carla M Bann; Benjamin A Alman; Susan D Apkon; Angela Blackwell; Laura E Case; Linda Cripe; Stasia Hadjiyannakis; Aaron K Olson; Daniel W Sheehan; Julie Bolen; David R Weber; Leanne M Ward
Journal:  Lancet Neurol       Date:  2018-02-03       Impact factor: 44.182

Review 6.  Bone Health and Osteoporosis Management of the Patient With Duchenne Muscular Dystrophy.

Authors:  Leanne M Ward; Stasia Hadjiyannakis; Hugh J McMillan; Garey Noritz; David R Weber
Journal:  Pediatrics       Date:  2018-10       Impact factor: 7.124

7.  Bone Health and Endocrine Care of Boys with Duchenne Muscular Dystrophy: Data from the MD STARnet.

Authors:  David R Weber; Shiny Thomas; Stephen W Erickson; Deborah Fox; Joyce Oleszek; Shree Pandya; Yedatore Venkatesh; Christina Westfield; Emma Ciafaloni
Journal:  J Neuromuscul Dis       Date:  2018

Review 8.  Muscle-Bone Interactions in Pediatric Bone Diseases.

Authors:  Louis-Nicolas Veilleux; Frank Rauch
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

Review 9.  Bone Health in Childhood Chronic Disease.

Authors:  David R Weber
Journal:  Endocrinol Metab Clin North Am       Date:  2020-10-13       Impact factor: 4.741

10.  Systemic investigation of bone and muscle abnormalities in dystrophin/utrophin double knockout mice during postnatal development and the mechanisms.

Authors:  Xueqin Gao; Ying Tang; Sarah Amra; Xuying Sun; Yan Cui; Haizi Cheng; Bing Wang; Johnny Huard
Journal:  Hum Mol Genet       Date:  2019-05-15       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.